Search

everythinglearnresearchcommunity

for

Search:↓

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

Early medical support for transgender youth is important for their health, with low regret for gender-affirming hormone use and a need for knowledgeable care providers.

Postpartum depression is linked to changes in brain chemicals, inflammation, stress, and certain genes, and can potentially be identified by markers like specific steroids, serotonin levels, and vitamin D levels.

Gender differences affect allergy prevalence, severity, and response to environmental toxins, with women often more affected than men.

17α-estradiol is a safe estrogen that might protect the brain and doesn't cause feminization, needing more research for treating brain diseases.

Oral estradiol works for many transgender women but needs personalized dosing and monitoring.

Testosterone is crucial for development, growth, and various body functions in mammals.

A postmenopausal woman's facial redness, acne, and excess hair were caused by too much hormone therapy for insomnia, but improved after stopping the treatment.

Using β-cyclodextrin derivatives improves the solubility and bioavailability of steroidal drugs.

Gender-affirming hormone therapy changes hair growth in transgender people, with feminizing therapy reducing hair and masculinizing therapy increasing it, but sometimes additional treatment is needed.

A nutrition program improved a young woman's concussion symptoms.

The healthcare for transgender veterans could be better with a more unified team approach.

Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.

Anabolic steroids can build muscle and strength but have risks and need more research on their clinical benefits and side effects.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

The report recommends personalized treatment for women's sexual dysfunctions and more research on effective therapies.

Testosterone therapy can help improve sexual desire and function in postmenopausal women but may cause side effects and is not FDA-approved for this use.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.

Cyclodextrins improve how steroid drugs work and are used in marketed medications and environmental applications.

FPHL is common in women, influenced by genetics and hormones, and can be treated with medications, laser therapy, or hair transplantation.

Primary care doctors should address female sexual dysfunctions to improve women's sexual health and life quality.

The conclusion is that there is a high demand for new contraceptives that provide both pregnancy prevention and protection against STIs, along with additional health benefits.

Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.

The document concludes that gender-affirming treatments are essential for transgender individuals and outlines safe hormone therapy practices.

Cell transplantation faces challenges in genitourinary reconstruction, but alternative tissue sources and microencapsulation show promise.

Transgender women can develop feminine traits and improve their quality of life through hormone therapy and surgery, but results vary and access to surgery can be limited.

Testosterone therapy for postmenopausal women appears safe and may protect against heart disease, but requires constant monitoring and more research for long-term effects.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.